ArticleGland surgery2025
Clinical characteristics and prognostic factors analysis of patients stricken with double primary breast and ovarian cancer based on the SEER database.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dual primary breast cancer (BC) and ovarian cancer (OC) represent a distinct subset of patients with diverse survival situation compared to those with a single primary BC or OC. Nonetheless, comprehensive research on their clinical characteristics and prognosis is lacking. This study conducted a retrospective analysis of clinical characteristics, survival outcomes, and prognostic factors of dual primary BC and OC patients. Methods: We applied the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database to identify patients with dual primary BC and primary OC (DPBOC) from 2000 to 2019, and divided patients into two groups: the BC-first group (BO group) and the OC-first group (OB group). Moreover, we employed Kaplan-Meier method to assess overall survival (OS), breast cancer-specific survival (BCSS), and ovarian cancer-specific survival (OCSS), and the Cox proportional hazards model to analyze prognostic factors. Results: There were 1,074 patients enrolled, 665 in the BO group and 409 in the OB group. The median time interval was for 48 (range, 0-228) months. There were significant differences in serous carcinoma and OC tumor stage between the two groups (P<0.001; P<0.001). There was no significant difference in BCSS between the two groups (Log-rank P=0.67), but the BO group had inferior OS and OCSS than the OB group (Log-rank P<0.001). Patients with an interval of ≥48 months had a significantly lower risk of death [hazard ratio (HR) =0.323, 95% confidence interval (CI): 0.264-0.395, P<0.001; HR =0.527, 95% CI: 0.305-0.908, P=0.02; HR =0.709, 95% CI: 0.560-0.897, P=0.004]. Conclusions: OC primarily determines the survival outcomes of DPBOC. Patients with BC as the first primary cancer (FPC) have a worse prognosis than patients with OC as FPC. After a diagnosis of BC or OC, we should pay close attention to another site, particularly after BC diagnosis, and monitor screening for ovarian lesions as early as feasible, as well as strengthening the treatment for OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.